AstraZeneca (NYSE:AZN) is scheduled to release its earnings data before the market opens on Thursday, February 14th. Analysts expect AstraZeneca to post earnings of $0.76 per share for the quarter.
Shares of AstraZeneca stock opened at $36.68 on Tuesday. AstraZeneca has a twelve month low of $32.69 and a twelve month high of $41.78. The stock has a market cap of $93.74 billion, a PE ratio of 8.57, a price-to-earnings-growth ratio of 1.96 and a beta of 0.51. The company has a current ratio of 0.86, a quick ratio of 0.66 and a debt-to-equity ratio of 1.36.
Several equities analysts recently issued reports on AZN shares. Exane BNP Paribas started coverage on shares of AstraZeneca in a report on Tuesday, February 5th. They set an “outperform” rating for the company. Investec downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Monday, November 19th. HSBC reissued a “sell” rating on shares of AstraZeneca in a report on Monday, November 12th. ValuEngine downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Tuesday, January 15th. Finally, UBS Group reissued a “hold” rating on shares of AstraZeneca in a report on Monday, November 19th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $45.50.
WARNING: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2019/02/12/astrazeneca-azn-to-release-earnings-on-thursday.html.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: What is an Initial Public Offering (IPO)?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.